ABVC BioPharma, Inc. (ABVC) Income Statement
ABVC 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsABVC revenue and net income
Where ABVC's revenue goes
2025Each bar shows an amount and its share of revenue. ABVC kept −993.6% of revenue as net income.
ABVC profit margins
ABVC growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +56.2% | −6.4% | +10.5% | +72.8% |
| Gross profit | +56.4% | +5.2% | +11.4% | +75.7% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ABVC quarterly EPS vs estimates
ABVC BioPharma beat the analyst EPS estimate in 1 of the last 3 quarters. Next report: October 30, 2026.
ABVC income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $795,950 | $509,589 | $152,430 | $969,783 | $355,797 | $483,045 | $701,719 | $6,956 | $3,196 | $32 |
| Cost of revenue | $504,834 | $763 | $302,037 | $286,415 | $5,086 | $18,716 | $20,137 | $228,890 | $2,249 | $32 |
| Gross profit | $795,950 | $508,826 | −$149,607 | $683,368 | $350,711 | $464,329 | $681,582 | −$221,934 | $947 | −$32 |
| Research & development | $121,085 | $179,272 | $1.1M | $2.7M | $1.0M | $549,658 | $1.0M | $988,721 | $3.2M | $10.0M |
| Sales, general & admin | $7.0M | $5.0M | $5.6M | $13.1M | $11.1M | $8.4M | $3.1M | $1.4M | $1.7M | $4.5M |
| Total operating expenses | $7.2M | $5.2M | $6.6M | $15.8M | $12.1M | $9.0M | $4.1M | $2.6M | $4.1M | $11.0M |
| Operating income | −$7.2M | −$4.7M | −$6.8M | −$15.1M | −$11.7M | −$8.5M | −$3.5M | −$2.8M | −$4.1M | −$11.0M |
| Interest income | $167,103 | $87,358 | $185,481 | $187,817 | $43,196 | $71,045 | $23,344 | $93 | $180 | $361 |
| Interest expense | $415,890 | $825,899 | $1.3M | $293,968 | $227,210 | $405,032 | $482,014 | $462,751 | $103,460 | $10,170 |
| Income before taxes | −$8.4M | −$5.4M | −$8.0M | −$15.5M | −$11.2M | −$10.8M | −$4.0M | −$6.4M | −$4.2M | −$11.0M |
| Income taxes | $24,154 | −$110,539 | $256,006 | $797,778 | $825,024 | −$220,352 | −$77,041 | −$365,097 | $830 | $836 |
| Net income | −$7.9M | −$4.9M | −$7.8M | −$16.4M | −$12.8M | −$9.8M | −$3.6M | −$5.6M | −$4.2M | −$11.0M |
| EBITDA | −$7.4M | −$4.3M | −$6.3M | −$15.2M | −$11.0M | −$10.4M | −$3.5M | −$5.9M | −$4.1M | −$11.0M |
| EPS (diluted) | −$0.34 | −$0.37 | −$2.49 | −$2.05 | −$4.65 | −$2.70 | −$0.22 | −$0.47 | −$0.46 | −$9.30 |
| Gross margin | 100.0% | 99.9% | −98.1% | 70.5% | 98.6% | 96.1% | 97.1% | −3,190.5% | 29.6% | −100.0% |
| Operating margin | −898.5% | −923.3% | −4,439.2% | −1,558.5% | −3,290.1% | −1,760.9% | −492.9% | −40,031.1% | −129,497.8% | −34,366,359.4% |
| Net margin | −993.6% | −962.1% | −5,109.3% | −1,693.5% | −3,608.5% | −2,027.0% | −519.0% | −80,152.1% | −132,755.3% | −34,399,184.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $795,950 | $0 | $1,966 | $1,966 | $389,276 | $117,142 | $1,205 | $2,165 | $15,884 |
| Cost of revenue | $0 | $92,156 | $214,043 | $0 | $80,832 | $113,948 | $0 | $296 | $190 | $277 | $139,206 | $29,614 |
| Gross profit | $0 | −$92,156 | −$795,950 | $795,950 | −$80,832 | $1,966 | $1,966 | $388,980 | $116,952 | $928 | −$137,041 | −$13,730 |
| Research & development | $22,707 | $33,100 | $29,058 | $29,890 | $33,276 | $28,861 | $31,980 | $37,825 | $40,401 | $69,066 | $72,185 | $141,310 |
| Sales, general & admin | $503,778 | $1.5M | $2.2M | $1.9M | $2.3M | $665,430 | $304,144 | $653,471 | $944,180 | $2.8M | $1.8M | $2.0M |
| Total operating expenses | $779,526 | $1.6M | $2.2M | $2.0M | $2.3M | $693,005 | $336,124 | $691,296 | $977,059 | $2.8M | $1.8M | $2.1M |
| Operating income | −$779,526 | −$1.6M | −$3.0M | −$2.0M | −$2.3M | −$693,005 | −$334,158 | −$302,316 | −$860,107 | −$2.8M | −$2.0M | −$2.2M |
| Interest income | $683 | $3,765 | $81,606 | $47,287 | $19,139 | $19,071 | $11,907 | $44,261 | $27,141 | $4,049 | $37,483 | $40,246 |
| Interest expense | $42,323 | $49,377 | $32,551 | $30,959 | $129,413 | $222,967 | $338,349 | $219,533 | $207,079 | $181,676 | $1.1M | $1.2M |
| Income before taxes | −$810,481 | −$1.7M | −$3.8M | −$2.1M | −$2.3M | −$944,190 | $128,943 | −$487,076 | −$1.2M | −$2.9M | −$3.2M | −$3.4M |
| Income taxes | −$736,934 | −$1.6M | $527 | $527 | $23,627 | — | — | $355 | −$110,894 | −$3.9M | $175,310 | −$999 |
| Net income | −$736,934 | −$1.6M | −$3.6M | −$2.0M | −$2.3M | −$842,075 | $229,304 | −$394,769 | −$942,336 | −$2.8M | −$3.1M | −$3.3M |
| EBITDA | −$678,663 | −$1.5M | −$3.6M | −$2.0M | −$2.1M | −$607,275 | — | −$160,291 | −$836,900 | −$2.6M | −$2.0M | −$2.1M |
| EPS (diluted) | −$0.03 | — | — | −$0.05 | −$0.13 | $0.02 | — | −$0.01 | −$0.09 | −$0.40 | −$0.39 | −$0.82 |
| Gross margin | — | — | — | 100.0% | — | 100.0% | 100.0% | 99.9% | 99.8% | 77.0% | −6,329.8% | −86.4% |
| Operating margin | — | — | — | −246.8% | — | −35,249.5% | −16,996.8% | −77.7% | −734.2% | −235,539.8% | −90,605.5% | −13,566.3% |
| Net margin | — | — | — | −256.6% | — | −42,831.9% | 11,663.5% | −101.4% | −804.4% | −235,203.2% | −143,692.1% | −20,885.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ABVC's financial statements (latest annual report filed March 3, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ABVC financial results
In fiscal year 2025 (ended December 31, 2025), ABVC BioPharma reported revenue of $0.8 million, up 56.2% from the year before. It had a net loss of $7.9 million, a net profit margin of −993.6%. Diluted earnings per share came to −$0.34. Over five years revenue grew at an average rate of 10.5% a year.
See the ABVC stock overview for the latest quote and news, or the ABVC chart for price history and technical indicators.
ABVC income statement FAQ
What is ABVC BioPharma's annual revenue?
ABVC BioPharma reported total revenue of $0.8 million for fiscal year 2025, which ended on December 31, 2025. That was up 56.2% from $0.5 million the previous year.
Is ABVC BioPharma profitable?
No. ABVC BioPharma reported a net loss of $7.9 million in fiscal 2025, a net profit margin of −993.6%; its operating margin was −898.5%.
What is ABVC BioPharma's gross margin?
ABVC BioPharma's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, ABVC BioPharma kept $100 after the direct cost of its products and services.
How much does ABVC BioPharma spend on research and development?
ABVC BioPharma spent $0.1 million on research and development in fiscal 2025, 15.2% of revenue.
How fast is ABVC BioPharma growing?
Revenue grew 10.5% a year on average over the last five fiscal years, from $0.5 million to $0.8 million.
What are ABVC BioPharma's earnings per share?
ABVC BioPharma earned $-0.34 per diluted share in fiscal 2025, compared with $-0.37 a year earlier.
When will ABVC BioPharma report its next earnings?
ABVC BioPharma is expected to report results for the quarter ending September 30, 2026 on October 30, 2026.
When does ABVC BioPharma's fiscal year end?
ABVC BioPharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 3, 2026.